Regeneron Pharmaceuticals' Eylea, or aflibercept injection, was approved by the FDA as treatment for diabetic retinopathy at any stage. The FDA approval was based on the Phase III PANORAMA trial, which showed that of the 402 enrolled patients, 80% of patients treated with the drug every eight weeks experienced a two-step or greater improvement in their scores on the diabetic retinopathy severity scale from baseline, compared with 65% of those who received treatment every 16 weeks and 15% of patients given sham injection.
Regeneron receives FDA approval for diabetic retinopathy drug
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.